Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Study to Evaluate the Glucose Response of G-Pen (Glucagon Injection) in Pediatric Patients With Type 1 Diabetes

Trial Profile

A Phase 3 Study to Evaluate the Glucose Response of G-Pen (Glucagon Injection) in Pediatric Patients With Type 1 Diabetes

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Nov 2018

At a glance

  • Drugs Glucagon (Primary)
  • Indications Hypoglycaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors XERIS Pharmaceuticals
  • Most Recent Events

    • 07 Nov 2018 According to a Xeris Pharmaceuticals media release, NDA for the glucagon pen for the treatment of severe hypoglycemia has been submitted.The FDA has accepted for review the New Drug Application (NDA), and assigned a PDUFA goal date of June 10, 2019.
    • 31 Aug 2018 Biomarkers information updated
    • 25 Jun 2018 Results presented at the American Diabetes Association's 78th Scientific Sessions 2018, as per a Xeris Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top